Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,928Revenue $M0Net Margin (%)0Z-Score
Enterprise Value $M4,922EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %2.0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 72.682%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 72.6819%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 72.6847%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 72.6849%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 72.6849%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 72.6852%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 72.6856%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 72.6857%Reduce -93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 72.6860%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 72.6859%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 72.6856%Reduce -43.59%6,600
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 72.6859%New holding11,700
XLVBill Gates 2009-06-30 Sold Out -4.19%$23.76 - $26.53
($25.04)
$ 72.6866%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Power, Patrick EdwardDirector, Senior Officer 2015-04-24Buy60,000$0.06123883.33view
Power, Patrick EdwardDirector, Senior Officer 2015-04-24Buy40,000$0.06123883.33view
Kovacevic, John GianniDirector, Senior Officer 2015-04-24Buy126,000$0.06123883.33view
Clark, Gilbert PercyDirector 2015-04-24Buy2,500$0.1841227.78view
Cope, Gary GordonSenior Officer 2015-04-24Buy23,500$0.2233713.64view
Casswell, Kim CharisseSenior Officer 2015-04-24Sell1,300$4.341614.06view
Barnes, Peter DerekDirector 2015-04-24Buy10,000$7.96834.55view
Patricio, Richard JDirector, Director or Senior Officer of 10% Securi 2015-04-24Sell9,500,000$0.5812725.86view
Tiberio, DanielDirector 2015-04-24Buy10,000$0.2925551.72view
Erickson, David Henry10% Security Holder, Director, Senior Officer 2015-04-24Buy6,000$0.6810839.71view

Press Releases about XLV :

    Quarterly/Annual Reports about XLV:

      News about XLV:

      Articles On GuruFocus.com
      S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
      Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
      Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 


      More From Other Websites
      U.S. Tech, Dollar & Health Care ETFs To Watch This Week Apr 26 2015
      Johnson & Johnson’s Revenues Take a Hit with Stronger Dollar Apr 24 2015
      Mylan lowers price for Perrigo Apr 24 2015
      Pisani's market open: Seattle's finest Apr 24 2015
      What Are the Conditions of the Mylan-Teva Deal? Apr 23 2015
      The Teva-Mylan Combination: What’s the Rationale? Apr 23 2015
      AQR Capital Enhances Pfizer Holdings by 33% Apr 23 2015
      Rich Pzena hunts for value Apr 23 2015
      Rich Pzena: If rates go up, these stocks could lag Apr 23 2015
      HCA Holdings: What to Expect from 1Q15 May Earnings Release Apr 23 2015
      The Cyclical Aspect of the Labor Market Conundrum Apr 23 2015
      AQR Capital More Than Doubles its Holdings in Gilead Sciences Apr 23 2015
      The Mylan–Teva Deal: Arbitrage Spread Analysis Apr 22 2015
      Teva Pharmaceuticals Makes a Hostile Bid for Mylan Apr 22 2015
      US Equities Headwinds: Earnings and Valuation Apr 22 2015
      ETFs That Outperform in Late Stage, Recession, and Trough Apr 22 2015
      An Investor’s Key Guide to Business Cycle Investing Apr 22 2015
      Medicare Advantage Enrollments Drive Humana’s 1Q15 Revenue Growth Apr 21 2015
      What to Expect from Humana’s 1Q15 Earnings Apr 21 2015
      No link with autism and MMR vaccine: Study Apr 21 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK